Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity ...

Briefly, antihuman rabbit monoclonal antibodies for FOXP3 (1:50; #98377S, CST, Massachusetts, USA) and antihuman mouse monoclonal antibodies for CTLA-4 (1:100; #ab19792, Abcam, Cambridge, UK) were ...

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the ...

SAN DIEGO and SUZHOU, China - Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million ...

("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 bispecific ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Innate Pharma (NASDAQ:IPHA – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based ...